Bristol-Myers Squibb Company (BMY) · page 78 of 197
The slide uses a DCF model to cap the potential synergy value, explicitly noting that 100% cost elimination is unrealistic.
Activist deck · valuation_table · show_valuation_bridge · overcrowded density
Slide locked Sign in to view
Slide schematic 9/9
callout 1/1 list 2/2 paragraph 1/1 source-note 1/1 table 2/2 title 2/2
Components 9
primary bullet bullet paragraph source-note valuation valuation action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.